Karrie Kwan Ki Ko

Karrie Kwan Ki Ko

Auto-generated profile, based on publicly available information

Karrie Kwan Ki Ko

Department of Microbiology, Singapore General Hospital, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
KKKarrie K. K. Ko
Karrie K. K. Ko
KCKern Rei Chng
Kern Rei Chng
NNNiranjan Nagarajan
Niranjan Nagarajan

13 July 2024 in The Lancet Microbe
Verified
Journal Article
Open access
CSChayaporn Suphavilai
Chayaporn Suphavilai
KKKarrie Kwan Ki Ko
Karrie Kwan Ki Ko
KLKar Mun Lim
Kar Mun Lim
MTMei Gie Tan
Mei Gie Tan
PBPatipan Boonsimma
Patipan Boonsimma
NNNiranjan Nagarajan
Niranjan Nagarajan
The emerging fungal pathogen Candida auris poses a serious threat to global public health due to its worldwide distribution, multidrug resistance, high transmissibility, propensity to cause outbreaks, and high mortality. We aimed to characterise three unusual C auris isolates detected in Singapore, and to determine whether they constitute a novel clade distinct from all previously known C auris clades (I-V). In this genotypic and phenotypic study, we characterised three C auris clinical isolates, which were cultured from epidemiologically unlinked inpatients at a large tertiary hospital in Singapore. The index isolate was detected in April, 2023. We performed whole-genome sequencing (WGS) and obtained hybrid assemblies of these C auris isolates. The complete genomes were compared with representative genomes of all known C auris clades. To provide a global context, 3651 international WGS data from the National Center for Biotechnology Information (NCBI) database were included in a high-resolution single nucleotide polymorphism (SNP) analysis. Antifungal susceptibility testing was done and antifungal resistance genes, mating-type locus, and chromosomal rearrangements were characterised from the WGS data of the three investigated isolates. We further implemented Bayesian logistic regression models to classify isolates into known clades and simulate the automatic detection of isolates belonging to novel clades as their WGS data became available. The three investigated isolates were separated by at least 37 000 SNPs (range 37 000-236 900) from all existing C auris clades. These isolates had opposite mating-type allele and different chromosomal rearrangements when compared with their closest clade IV relatives. The isolates were susceptible to all tested antifungals. Therefore, we propose that these isolates represent a new clade of C auris, clade VI. Furthermore, an independent WGS dataset from Bangladesh, accessed via the NCBI Sequence Read Archive, was found to belong to this new clade. As a proof-of-concept, our Bayesian logistic regression model was able to flag these outlier genomes as a potential new clade. The discovery of a new C auris clade in Singapore and Bangladesh in the Indomalayan zone, showing a close relationship to clade IV members most commonly found in South America, highlights the unknown genetic diversity and origin of C auris, particularly in under-resourced regions. Active surveillance in clinical settings, along with effective sequencing strategies and downstream analysis, will be essential in the identification of novel strains, tracking of transmission, and containment of adverse clinical effects of C auris infections. Duke-NUS Academic Medical Center Nurturing Clinician Researcher Scheme, and the Genedant-GIS Innovation Program.

29 June 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
KKKarrie K. K. Ko
Karrie K. K. Ko
HYHatairat Yingtaweesittikul
Hatairat Yingtaweesittikul
TTThuan Tong Tan
Thuan Tong Tan
LWLimin Wijaya
Limin Wijaya
DCDelphine Yanhong Cao
Delphine Yanhong Cao
CSChayaporn Suphavilai
Chayaporn Suphavilai
The emergence of clinically important mutations described in this report highlights the need for sustained vigilance and containment measures when managing immunocompromised patients with persistent COVID-19. Even as jurisdictions across the globe start lifting pandemic control measures, immunocompromised patients with persistent COVID-19 constitute a unique group that requires close genomic monitoring and enhanced infection control measures, to ensure early detection and containment of mutations and variants of therapeutic and public health importance.

1 March 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CKChee Wai Ku
Chee Wai Ku
DSDurai Shivani
Durai Shivani
JKJacqueline Q.T. Kwan
Jacqueline Q.T. Kwan
SLSee Ling Loy
See Ling Loy
CEChristina Erwin
Christina Erwin
JCJerry.K.Y. Chan
Jerry.K.Y. Chan
Effective management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires large-scale testing to identify and isolate infectious carriers. Self-administered buccal swab and saliva collection are convenient, painless, and safe alternatives to the current healthcare worker (HCW)-collected nasopharyngeal swab (NPS). A cross-sectional single-centre study was conducted on 42 participants who had tested positive for SARS-CoV-2 via an NPS within the past 7 days. Real-time polymerase chain reaction (RT-PCR) was performed and cycle threshold (Ct) values were obtained for each test. The positive percent agreement (PPA), negative percent agreement (NPA), and overall agreement (OA) were calculated for the saliva samples and buccal swabs, and compared with NPS. Among the 42 participants, 73.8% (31/42) tested positive by any one of the three tests. With reference to NPS, the saliva test had PPA 66.7%, NPA 91.7%, and OA 69.0%; the buccal swab had PPA 56.7%, NPA 100%, and OA 73.8%. Self-collected saliva tests and buccal swabs showed only moderate agreement with HCW-collected NPS. Primary screening for SARS-CoV-2 may be performed with a saliva test or buccal swab, with a negative test warranting a confirmatory NPS to avoid false-negatives, minimize discomfort, and reduce the risk of spread to the community and HCWs.

9 February 2026 in Nature Methods
Verified
Journal Article
Open access
PDF file
MHMartin Hunt
Martin Hunt
AHAngie S. Hinrichs
Angie S. Hinrichs
DADaniel Anderson
Daniel Anderson
LKLily Karim
Lily Karim
BDBethany Dearlove
Bethany Dearlove
ZIZamin Iqbal
Zamin Iqbal
The majority of SARS-CoV-2 genomes obtained during the pandemic were derived by amplifying overlapping windows of the genome (‘tiled amplicons’), reconstructing their sequences and fitting them together. This leads to systematic errors in genomes unless the software is both aware of the amplicon scheme and of the error modes of amplicon sequencing. Additionally, over time, amplicon schemes need to be updated as new mutations in the virus interfere with the primer binding sites at the end of amplicons. Thus, waves of variants swept the world during the pandemic and were followed by waves of systematic errors in the genomes, which had significant impacts on the inferred phylogenetic tree. Here we reconstruct the genomes from all public data as of June 2024 using an assembly tool called Viridian ( https://github.com/iqbal-lab-org/viridian ), developed to rigorously process amplicon sequence data. With these high-quality consensus sequences we provide a global phylogenetic tree of 4,471,579 samples, viewable at https://viridian.taxonium.org . We provide simulation and empirical validation of the methodology, and quantify the improvement in the phylogeny.

6 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
CSChayaporn Suphavilai
Chayaporn Suphavilai
KKKarrie Kwan Ki Ko
Karrie Kwan Ki Ko
KLKar Mun Lim
Kar Mun Lim
MTMei Gie Tan
Mei Gie Tan
PBPatipan Boonsimma
Patipan Boonsimma
NNNiranjan Nagarajan
Niranjan Nagarajan
Summary: Background: The emerging fungal pathogen Candida auris poses a serious threat to global public health due to its worldwide distribution, multidrug-resistance, high transmissibility, propensity to cause outbreaks and high mortality rates. We report three C. auris isolates detected in Singapore, which are genetically distinct from all known clades (I-V) and represent a new clade (Clade VI). Methods: Three epidemiologically unlinked clinical isolates belonging to the potential new C. auris clade were whole-genome sequenced and phenotypically characterized. The complete genomes of these isolates were compared to representative genomes of all known clades. To provide a global context, 3,651 international whole-genome sequences (WGS) from the NCBI database were included in the high-resolution single nucleotide polymorphism (SNP) analysis. Antifungal resistance genes, mating type locus, and chromosomal rearrangements were characterized from the WGS data of the Clade VI isolates. We further implemented Bayesian logistic regression models to simulate the automatic detection of Clade V and VI as their WGS data became available. Findings: The three Clade VI isolates were separated by >36,000 SNPs from all existing C. auris clades. These isolates had opposite mating type allele and different chromosomal rearrangements when compared to their closest Clade IV relatives. As a proof-of-concept, our classification model was able to flag these outlier genomes as a potential new clade. Furthermore, an independent WGS submission from Bangladesh was found to belong to this new clade. Interpretation: The discovery of a new C. auris clade in Singapore and Bangladesh, showing close relationship to Clade IV members in South America, highlights the unknown genetic diversity and origin of C. auris , particularly in under-resourced regions. Active surveillance in clinical settings, along with effective sequencing strategies and downstream analysis, will be essential in the identification of novel strains, tracking of transmission, and containment of adverse clinical impacts caused by C. auris infections. Funding: This work was supported by the Singapore National Medical Research Council (NMRC) research training fellowship (MOH-FLWSHP19may-0005), the NCRS Duke-NUS Academic Medical Center Academic Clinical Program grant (09/FY2022/P1/17-A32, GRDUKP003401), and the Genedant-GIS Innovation Program grant. Research in context: Evidence before this study: We searched PubMed using the search terms “ Candida auris ” AND “clade”, for papers published between Jan 1, 2009, and July 1, 2023. This search retrieved 115 publications. 60 relevant publications were identified. 28 studies analyzed and discussed the molecular epidemiology of C. auris , including the description of C. auris clades, either in outbreak or surveillance settings. There were 11 case reports of C. auris clinical cases that included clade determination. Two studies focused on the detection and clade determination of C. auris from non-healthcare environments. Clade-specific characteristics were described or analyzed in 14 studies. One study applied machine learning to C. auris drug resistance analysis, but not for clade determination. Four studies focused on the description of potentially new C. auris lineages, subclades, or clades. All publications described isolates that belong to one of the five known C. auris clades (I-V). All publications found that strains from different clades differed by more than 35,000 SNPs, and that there are clade-specific differences in geographical distribution, phenotypic characteristics, antifungal susceptibility profile, outbreak potential, and clinical manifestations. The NCBI Pathogen Detection system contained 4,506 C. auris genomes on July 1, 2023. There were ten (0·22%) submissions from Southeast Asian countries and 92 (2·04%) submissions from South Asia and the Indian subcontinent, which are parts of the Indomalayan biogeographic realm. Added value of this study: To the best of our knowledge, we are the first group to perform hybrid assemblies on three representative isolates in a new C. auris clade, which is separated from all other existing clades (I-V) by >36,000 SNPs. Whole-genome SNP analysis and phenotypic characterization of these epidemiologically unlinked isolates detected in Singapore suggest that they represent a previously unreported sixth major clade. High-resolution SNP analysis of 3,651 international whole-genome sequences from the NCBI database, which generated the final dataset consisting of more than 6.6 million genome pairs, revealed six distinct genetic clusters representing the five known clades and the new sixth clade (Indomalayan). In addition, we demonstrate that a machine learning approach can be used to flag these outlier genomes for further investigations as soon as they become available, thus providing the earliest possible alert for potential new public health threats. Implications of all the available evidence: Despite the high antimicrobial resistance burden in Southeast Asia and South Asia, these regions are disproportionately underrepresented in terms of genomic surveillance of C. auris , a multidrug-resistant fungal pathogen. The detection of three epidemiologically unlinked C. auris isolates in Singapore belonging to a new C. auris clade suggests that yet-to-be-reported strains may be circulating in the region. Given the propensity for multidrug resistance, healthcare-associated infection outbreaks, and the associated high mortality, active surveillance and continued vigilance is necessary.